217.94 0.00 (0.00%)
After hours: 5:15PM EDT
|Bid||218.61 x 1000|
|Ask||218.64 x 1000|
|Day's Range||217.79 - 220.68|
|52 Week Range||144.75 - 222.59|
|Beta (3Y Monthly)||1.05|
|PE Ratio (TTM)||23.32|
|Earnings Date||Oct 23, 2019 - Oct 28, 2019|
|Forward Dividend & Yield||2.08 (0.95%)|
|1y Target Est||227.31|
President and COO of Stryker Corp (30-Year Financial, Insider Trades) Timothy J Scannell (insider trades) sold 4,666 shares of SYK on 08/16/2019 at an average price of $217.08 a share. Continue reading...
Spencer S. Stiles will serve as Group President of Orthopaedics and Spine and will oversee Stryker’s Joint Replacement, Trauma & Extremities and Spine divisions. J. Andrew Pierce, Group President of MedSurg and Neurotechnology will oversee Stryker’s Instruments, Medical, Endoscopy, Sustainability and Neurotechnology businesses.
Pacific Biosciences (PACB) Q2 results gain from higher revenues and strong segmental performance. Contraction in gross margin remains a woe.
Allscripts (MDRX) second-quarter results gain from growth in bookings and solid show by client services segment. Contraction in operating margin remains a woe.
Tandem Diabetes' (TNDM) t:slim X2 Insulin pump's strength in domestic sales along with expansion in international markets during Q2 is encouraging.
Cardinal Health (CAH) Q4 results benefit from strong performance by Pharmaceutical segment and higher revenues. However, contraction in gross margin remains a concern.
We are upbeat about the year-over-year uptick in Coronary and peripheral device revenues within Cardiovascular Systems' (CSII) domestic market.
The year-over-year improvement in Insulet's (PODD) revenues owing to the solid adoption of Omnipod system, both in the United States and the international markets, encourages us.